Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over
single-dose study employing administration of two oral formulations of crizotinib (OLF and
FC) in the fasted state to healthy adult subjects. Twenty-two (22) subjects will be enrolled
to obtain at least 20 evaluable subjects who complete the study. Each subject will receive
two treatments (A and B) with a washout period of at least 14 days between each treatment.